Metformin (generic), Glucophage Newswire

Metformin (generic), Glucophage Newswire

Comprehensive Real-Time News Feed for Metformin (generic), Glucophage.

Results 1 - 20 of 364 in Metformin (generic), Glucophage

  1. Type 2 Diabetes Therapeutic and Drug Pipeline Review 2026Read the original story

    Wednesday | World News Report

    Summary While the global T2D market is crowded with inexpensive generics and marked by a pipeline filled with me-too drugs, expects this market to undergo substantial growth between 2016 and 2026, doubling over the forecast period. The main driver of this enormous expansion will be the dramatic increase in disease prevalence, which is attributable to increased life expectancy and an increasingly sedentary and stressful lifestyle.


  2. Brain glucose responses diminish with diabetes, obesityRead the original story w/Photo

    Monday Nov 20 | PhysOrg Weblog

    The rise of brain glucose levels is blunted during hyperglycemia in adults with obesity and type 2 diabetes mellitus , according to a study published online Oct. 19 in JCI Insight . Janice J. Hwang, M.D., from the Yale School of Medicine in New Haven, Connecticut, and colleagues conducted 1H magnetic resonance spectroscopy scanning of the occipital lobe to measure the change in intracerebral glucose levels during a two-hour hyperglycemic clamp among 25 participants .


  3. Preventing type 2 diabetes: systematic review of studies of...Read the original story

    Monday Nov 20 | CiteULike

    Preventing type 2 diabetes: systematic review of studies of cost-effectiveness of lifestyle programmes and metformin, with and without screening, for pre-diabetes To insert individual citation into a bibliography in a word-processor, select your preferred citation style below and drag-and-drop it into the document. CiteULike organises scholarly papers or literature and provides bibliographic for universities and higher education establishments.


  4. First-line metformin use for DM up; sulfonylurea use downRead the original story w/Photo

    Sunday Nov 19 | PhysOrg Weblog

    Among patients with type 2 diabetes initiating antidiabetes drugs , first-line use of metformin has increased since 2005, while sulfonylureas have remained the most popular second-line agent, according to a study published online Nov. 6 in Diabetes Care . Olga Montvida, from Queensland University of Technology in Australia, and colleagues used data from the U.S. Centricity Electronic Medical Records to identify 1,023,340 patients with type 2 diabetes who initiated any ADD and 357,482 patients who initiated second-line ADD after first-line metformin .


  5. Americans Must Change Our Unhealthy Lifestyles to Combat Type 2 DiabetesRead the original story w/Photo

    Thursday Nov 16 | US News & World Report

    Everyone has their Thanksgiving favorite. For some, it's turkey. For most, it's fixings and desserts - sweet and rich - that appeal.


  6. The gene mutation that makes some live 10 years longerRead the original story w/Photo

    Wednesday Nov 15 | South China Morning Post

    Discovery of mutation which appears to protect against biological ageing raises hopes for new treatments to prevent age-related disorders The discovery of a rare genetic mutation that prolongs human life has raised hopes for new treatments to combat ageing and prevent age-related disorders from heart disease to dementia. Researchers spotted the mutation in an Amish population in Indiana where carriers were found to have better metabolic health, far less diabetes, and tended to live a decade longer than others in the community.


  7. The 4 common mistakes all prediabetics must avoid to prevent diabetesRead the original story

    Wednesday Nov 15 | MSN Healthy Living

    In other words, 'This is your chance to take control,' says Matt Longjohn, MD, MPH, senior director of chronic disease prevention for the YMCA-USA. 'Research proves that some simple, daily lifestyle changes can dramatically cut the risk for developing diabetes over the next couple of years by 58 percent, which is better than what is seen with frequently prescribed medications like metformin.'


  8. Glucose Management in Hospitalized PatientsRead the original story

    Wednesday Nov 15 | American Academy of Family Physicians

    Glucose management in hospitalized patients poses challenges to physicians, including identifying blood glucose targets, judicious use of oral diabetes mellitus medications, and implementing appropriate insulin regimens. Uncontrolled blood glucose levels can lead to deleterious effects on wound healing, increased risk of infection, and delays in surgical procedures or discharge from the hospital.


  9. African-American women with type 2 diabetes may have higher risk for ER-neg breast cancerRead the original story w/Photo

    Tuesday Nov 14 | PhysOrg Weblog

    Among African-American women, those with type 2 diabetes may have a higher risk of developing estrogen receptor -negative breast cancer. The study was published in Cancer Research , a journal of the American Association for Cancer Research, by Julie R. Palmer, ScD, associate director of Boston University's Slone Epidemiology Center, professor of epidemiology at Boston University School of Public Health, and associate director for population sciences at the BU-BMC Cancer Center The majority of breast cancers are ER-positive; this type of breast cancer is the easiest to treat and has the highest survival rate.


  10. Curcumin Beats Diabetes Drug at Lowering Blood Sugar: StudyRead the original story w/Photo

    Tuesday Nov 14 | News Max

    Curcumin, a component of the popular East Asian spice turmeric, is 400 times more powerful than the common diabetes drug Metformin in improving insulin sensitivity and helping to reverse Type 2 diabetes. That's the upshot of a new study published by Biochemistry and Biophysical Research Communications that is the latest to find that the popular spice used in curry dishes for centuries has extraordinary health benefits.


  11. You are what you eat: U of S research on food and genesRead the original story w/Photo

    Saturday Nov 11 | Sheaf

    With so much information out there, it can be hard to navigate the murky waters of how your diet influences your body. Everyone's seen internet claims with various nutrients suggested as the key to a healthy life, but only scientific research can actually tell us what's truly best for us.


  12. Health Roundup: Parkinson's editionRead the original story

    Wednesday Nov 1 | Business of Life

    A drug prescribed for diabetes patients reduces the risk of developing Parkinson's disease by more than a quarter, a major study has found. Researchers from the University of Bergen in Norway discovered glitazones had a protective effect against the degenerative neurological disease.


  13. New Type of Diabetes Discovered: Are You at Risk?Read the original story w/Photo

    Wednesday Nov 8 | News Max

    British scientists have made a starting discovery: University of Surrey researchers have identified a new type of diabetes they call Type 3c. Andrew McGovern, a British clinical researcher, said he and his colleagues have determined this new form of the metabolic disease is caused by damage to the pancreas from inflammation called pancreatitis, tumors of the pancreas, or surgery.


  14. Controlled-Release Drug Delivery Technology Market show exponential growth by 2027Read the original story w/Photo

    Monday Nov 6 |

    Specific focus on the quality-by-design approaches for the robust design of dosage forms is expected to change the future landscape of controlled-release drug delivery technologies. While conventional hydrophilic matrix based technologies such as Accuform are being used in the market for several years, recent advancements in the development of oral drug delivery systems such as gastro-retentive drug delivery for controlled release, buoyant systems, mucoadhesive systems for regulated release of anti-viral medications etc.


  15. Oral Antidiabetic Drugs Market Size & Share to Touch US $35.91 Billion by 2022: A to Z ResearchRead the original story

    Friday Nov 3 | SBWire

    According to the report, the global oral antidiabetic drug market accounted for USD 19.94 billion in 2016 and is expected to reach USD 35.91 billion by 2022, growing at a CAGR of around 10.2% between 2017 and 2022. Diabetes is a group of metabolic disorder characterized by the presence of high blood glucose level than normal level in an individual.


  16. This National Diabetes Month, be the center of your diabetes careRead the original story

    Wednesday Nov 1 | National Institutes of Health

    Statement from Dr. Griffin P. Rodgers, Director, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health. More than 30 million people in the United States have diabetes - and each one is the most important member of their diabetes care team.


  17. Sulfonylureas as Initial Treatment for Type 2 Diabetes and the Risk of Severe Hypoglycemia.Read the original story

    Wednesday Nov 1 | CiteULike

    The magnitude of the risk of severe hypoglycemia associated with sulfonylureas as the initial treatment for type 2 diabetes in the real-world setting is unknown. We assessed the risk of severe hypoglycemia associated with initiating monotherapy with sulfonylurea compared to metformin for the treatment of type 2 diabetes.


  18. LixisenatideRead the original story

    Wednesday Nov 1 | P&T Community

    According to the Centers for Disease Control and Prevention, 29.1 million people in the United States have diabetes , accounting for $245 billion in health care costs. 1 The increased prevalence of the disease over the last several decades, along with the economic burden, warrants great attention to clinical management.


  19. Statins Heighten Type 2 Diabetes Risk 30% in Susceptible PatientsRead the original story

    Tuesday Oct 31 | US Pharmacist

    The association between long-term use of statins and the development of type 2 diabetes has been demonstrated in several studies, but new research actually helps quantify the risk in susceptible patients. The report, published in the online journal BMJ Open Diabetes Research & Care , suggests that the elevated risk is 30%.


  20. Exclusive: U.S. states to expand generic drug price-fixing suit - sourcesRead the original story w/Photo

    Tuesday Oct 31 | Reuters

    Forty-six U.S. state attorneys general will seek to expand a lawsuit alleging price fixing of generic drugs to 18 companies and 15 medicines on Tuesday, including Novartis AG's in Connecticut. The new complaint will address the relationships between such parties as wholesalers, distributors, large pharmacies and supermarkets, the sources said, adding that it will also cover the agreements with manufacturers to keep prices high.